ValitaCell, an Irish biotechnology company that creates analytical products and technologies for the biopharmaceutical industry, has been bought by Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation.
Headquartered in Dublin and also with operations in Galway, ValitaCell creates analytical technologies and products for the biopharmaceutical industry with the goal of reducing new therapeutics' cost and time to market.
Its technologies are patented in key international markets and the company has been honored with several awards, including the Irish Pharmaceutical Awards' Pharma Start-up of the Year in 2017 and InterTrade Ireland’s Seedcorn awards.
It also was recognised as one of the most successful Irish companies in Horizon 2020.
Under the terms of the deal, ValitaCell locations in Dublin and Galway will remain operational and are anticipated to grow in response to business needs.
"Throughout our trusted partnership with ValitaCell, we have long admired their innovative offerings and industry expertise," said Jason Lanie, Vice President and General Manager of the Biotechnology Business Unit at Beckman Coulter Life Sciences.
"Their leading portfolio of products complement Beckman Coulter Life Sciences' existing and future product portfolio, and are designed with the same goal of providing faster cellular analysis while decreasing the risk of errors," he added.
